FibroBiologics shares surge 23.91% after-hours after Canadian patent for cachexia treatment expands IP portfolio and targets $3.2B market.

FibroBiologics surged 23.91% in after-hours trading following the announcement that the Canadian Intellectual Property Office issued Patent No. 3118732 for its fibroblast-based treatment of cachexia. The patent strengthens the company’s intellectual property portfolio and positions it to address a $3.2 billion cancer cachexia market by 2032. The filing covers methods using immune-modulating fibroblasts to reduce inflammation and reverse weight loss, underscoring the company’s innovative approach to treating a condition with significant unmet medical needs. CEO Pete O’Heeron highlighted the milestone as a critical step in advancing regenerative therapies, reinforcing investor confidence in FibroBiologics’ long-term potential.